Literature DB >> 8529431

Concentration of cephalosporins in tissues of the head and neck after parenteral infusion.

W Maier1, J Strutz.   

Abstract

Cephalosporins are successfully used in the therapy of acute sinusitis, purulent parotitis, and lymphadenitis. Anti-infectious prophylaxis in major head and neck surgery may be performed with cephalosporins as first choice. For sufficient prophylaxis or therapy, an effective level of the antibiotic drug in the serum and tissue of the target organs is necessary. In a comparative investigation, we measured serum and tissue levels of three regions of the head and neck (parotid glands, paranasal sinuses, soft tissue of the neck) of the second-generation cephalosporins, cefuroxime and cefotiam, after a single parenteral infusion. Both antibiotics reach levels which are effective against bacteria typically causing spontaneous or postoperative infection of head and neck tissue. Effective levels of cefuroxime both at the investigated tissue sites and in serum are greater than those of cefotiam, and cefuroxime is eliminated from serum less rapidly. The pharmacologic data show that both drugs are suitable for therapy and perioperative prophylaxis of purulent head and neck infections, but various data indicate that there is an advantage in favor of cefuroxime.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529431     DOI: 10.1159/000239377

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  [Bacterial sialadenitis].

Authors:  H Maier; M Tisch
Journal:  HNO       Date:  2010-03       Impact factor: 1.284

2.  Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial.

Authors:  Edin Mujagic; Tibor Zwimpfer; Walter R Marti; Marcel Zwahlen; Henry Hoffmann; Christoph Kindler; Christoph Fux; Heidi Misteli; Lukas Iselin; Andrea Kopp Lugli; Christian A Nebiker; Urs von Holzen; Fabrizio Vinzens; Marco von Strauss; Stefan Reck; Marko Kraljević; Andreas F Widmer; Daniel Oertli; Rachel Rosenthal; Walter P Weber
Journal:  Trials       Date:  2014-05-24       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.